BLIS Technologies Past Earnings Performance
Past criteria checks 3/6
BLIS Technologies's earnings have been declining at an average annual rate of -39.9%, while the Pharmaceuticals industry saw earnings growing at 35.1% annually. Revenues have been growing at an average rate of 1% per year. BLIS Technologies's return on equity is 5.6%, and it has net margins of 5.6%.
Key information
-39.9%
Earnings growth rate
-40.6%
EPS growth rate
Pharmaceuticals Industry Growth | 35.6% |
Revenue growth rate | 1.0% |
Return on equity | 5.6% |
Net Margin | 5.6% |
Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
Recent updates
BLIS Technologies (NZSE:BLT) Is In A Strong Position To Grow Its Business
Dec 05Calculating The Intrinsic Value Of BLIS Technologies Limited (NZSE:BLT)
Mar 08BLIS Technologies Limited (NZSE:BLT) Insiders Have Been Selling
Feb 09BLIS Technologies Limited (NZSE:BLT) Stock Has Shown Weakness Lately But Financials Look Strong: Should Prospective Shareholders Make The Leap?
Jan 21I Ran A Stock Scan For Earnings Growth And BLIS Technologies (NZSE:BLT) Passed With Ease
Jan 03Should You Use BLIS Technologies's (NZSE:BLT) Statutory Earnings To Analyse It?
Dec 15Introducing BLIS Technologies (NZSE:BLT), The Stock That Soared 371% In The Last Three Years
Nov 28Revenue & Expenses Breakdown
How BLIS Technologies makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Mar 24 | 12 | 1 | 9 | 0 |
31 Dec 23 | 11 | 0 | 9 | 0 |
30 Sep 23 | 11 | 0 | 9 | 0 |
30 Jun 23 | 11 | -1 | 9 | 0 |
31 Mar 23 | 10 | -1 | 10 | 0 |
31 Dec 22 | 10 | -2 | 10 | 0 |
30 Sep 22 | 9 | -3 | 10 | 0 |
30 Jun 22 | 9 | -3 | 10 | 0 |
31 Mar 22 | 9 | -3 | 10 | 0 |
31 Dec 21 | 9 | -3 | 10 | 0 |
30 Sep 21 | 9 | -2 | 10 | 0 |
30 Jun 21 | 10 | -1 | 9 | 0 |
31 Mar 21 | 11 | 1 | 8 | 0 |
31 Dec 20 | 11 | 1 | 8 | 0 |
30 Sep 20 | 12 | 2 | 8 | 0 |
30 Jun 20 | 11 | 2 | 7 | 0 |
31 Mar 20 | 11 | 2 | 7 | 0 |
31 Dec 19 | 11 | 2 | 7 | 0 |
30 Sep 19 | 11 | 2 | 6 | 0 |
30 Jun 19 | 10 | 1 | 6 | 0 |
31 Mar 19 | 8 | 0 | 6 | 0 |
31 Dec 18 | 7 | 0 | 7 | 0 |
30 Sep 18 | 6 | 0 | 7 | 0 |
30 Jun 18 | 6 | -1 | 6 | 0 |
31 Mar 18 | 5 | -1 | 5 | 0 |
31 Dec 17 | 5 | -1 | 3 | 0 |
30 Sep 17 | 5 | -2 | 1 | 0 |
30 Jun 17 | 6 | -1 | 1 | 0 |
31 Mar 17 | 7 | 0 | 0 | 0 |
31 Dec 16 | 7 | 0 | 0 | 0 |
30 Sep 16 | 7 | 0 | 0 | 0 |
30 Jun 16 | 6 | 0 | 0 | 0 |
31 Mar 16 | 6 | -1 | 0 | 0 |
31 Dec 15 | 5 | -1 | 0 | 0 |
30 Sep 15 | 4 | -1 | 0 | 0 |
30 Jun 15 | 3 | -1 | 0 | 0 |
31 Mar 15 | 3 | -1 | 0 | 0 |
31 Dec 14 | 2 | -1 | 0 | 0 |
30 Sep 14 | 2 | -2 | 0 | 0 |
30 Jun 14 | 1 | -2 | 0 | 0 |
31 Mar 14 | 1 | -2 | 0 | 0 |
31 Dec 13 | 1 | -2 | 0 | 0 |
Quality Earnings: BLT has high quality earnings.
Growing Profit Margin: BLT became profitable in the past.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: BLT has become profitable over the past 5 years, growing earnings by -39.9% per year.
Accelerating Growth: BLT has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: BLT has become profitable in the last year, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (26.6%).
Return on Equity
High ROE: BLT's Return on Equity (5.6%) is considered low.